Vasoactive Intestinal Peptide Receptors: A Molecular Target in Breast and Lung Cancer

Author(s): Terry W. Moody, Illana Gozes

Journal Name: Current Pharmaceutical Design

Volume 13 , Issue 11 , 2007

Become EABM
Become Reviewer
Call for Editor


Vasoactive intestinal peptide (VIP) receptors are present in the normal brain as well as periphery, and cancer cells. Three major types of VIP receptors include the VPAC1, VPAC2 and PAC1 receptors. VPAC1 receptors are present in high densities on human lung and breast cancer cells lines and biopsy specimens. Radiolabeled VIP analogues have been developed for imaging of lung and breast cancer. Synthetic VIP receptor antagonists inhibit the proliferation and potentiate the ability of chemotherapeutic agents to cause apoptosis of lung and breast cancer cells. VIP-chemotherapeutic conjugates have been synthesized which bind to VPAC1 receptors and are internalized, resulting in the killing of lung and breast cancer cells. These results suggest that VPAC1 receptors may be molecular targets for diagnosis, prevention and treatment of breast cancer as well as lung cancer.

Keywords: VIP, PACAP, receptors, breast cancer, lung cancer

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Published on: 01 March, 2012
Page: [1099 - 1104]
Pages: 6
DOI: 10.2174/138161207780619000
Price: $65

Article Metrics

PDF: 13